Dilemmas and options for COVID-19 vaccination in children

Table 2 Immunogenicity of the COVID-19 vaccine in children

Type of vaccination	Age group	Number of subjects	Vaccination status	Dosage	Immunogenicity (95% CI)	Detection time interval	Reference
BBIBP-CorV	3–5 years	81	First dose	2.0 µg	GMT: 14.5	28 days	[35]
		83		4.0 µg	GMT: 20.2
		82		8.0 µg	GMT: 21.3
	6–12 years	84		2.0 µg	GMT: 30.0
		84		4.0 µg	GMT: 54.1
		83		8.0 µg	GMT: 55.8
	13–17 years	83		2.0 µg	GMT: 48.0
		83		4.0 µg	GMT: 61.4
		82		8.0 µg	GMT: 80.2
CoronaVac	3–5 years	46	Second dose	1.5 µg	GMT: 94.1	28 days	[32]
	3–5 years	45		3.0 µg	GMT: 140.5
	6–11 years	69		1.5 µg	GMT: 90.3
	6–11 years	68		3.0 µg	GMT: 139.7
	12–17 years	71		1.5 µg	GMT: 78.3
	12–17 years	67		3.0 µg	GMT: 146.0
BNT162b2	5–11 years	264	Second dose	10.0 µg	GMT: 1197.6	1 month	[53]
	16–25 years	253	Second dose	30.0 µg	GMT: 1146.5	1 month	[53]
	12–15 years	190	Second dose	30.0 µg	GMNT₅₀: 1239.5	1 month	[34]
	16–25 years	170	Second dose	30.0 µg	GMNT₅₀: 705.1	1 month	[34]
mRNA-1273	6–23 months	230	Second dose	25.0 µg	GMC: 1781	28 days	[49]
	2–5 years	264		25.0 µg	GMC: 1410		[49]
	6–11 years	320		50.0 µg	GMPNAT: 1610		[33]
	12–17 years	340		100.0 µg	GMPNAT₅₀: 1401.7		[50]

Note: GMT, geometric mean titer; GMNT₅₀, geometric mean 50% neutralizing titer; GMC, geometric mean concentrations; GMPNAT, geometric mean pseudovirus neutralizing antibody titer; GMPNAT₅₀, geometric mean 50% pseudovirus neutralizing antibody titer.

ISSN: 1824-7288